Skip to main content
 CHANGE IN VISITATION GUIDELINES: Please read before visiting Rutgers Cancer Institute.

Print this page

ALLIANCE A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST): A screening trial for A081105 and E4512.

2.1 Primary Objectives
2.1.1 To centrally genotype resected lung adenocarcinomas for EGFR mutations and ALK
rearrangements to facilitate accrual to randomized adjuvant studies.
2.1.2 To obtain clinically annotated tumor tissue and patient-matched non-malignant DNA from
peripheral blood, as well as detailed epidemiologic and clinical follow-up data, to allow
clinically annotated advanced genomic analyses in concert with the NCI Center for Cancer
Genomics (CCG).
2.2 Secondary Objectives
2.2.1 To characterize the natural history of EGFR and ALK wild-type lung cancers to allow
subsequent development of targeted therapies against genotype-defined subpopulations in
the adjuvant and recurrent settings.
2.2.2 To cross-validate local genotyping assays for EGFR and ALK with a central reference
2.3 Exploratory/Other Objectives
2.3.1 To study the genomic evolution of lung cancers by comparing genomic characteristics at
resection and at recurrence.

Protocol Number: 031504
Phase: N/A
Applicable Disease Sites: Lung
Principal Investigator: Joseph Aisner M.D.
Scope: National
Participating Institutions:
  • RWJBarnabas Health
    • Community Medical Center
    • Monmouth Medical Center
    • Newark Beth Israel Medical Center
    • Robert Wood Johnson University Hospital, Hamilton
    • Robert Wood Johnson University Hospital, Somerset
    • Saint Barnabas Medical Center, Livingston
Inclusion & Exclusion Criteria

Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.

For further information about clinical trials, please contact us at 732-235-7356.